AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03926169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for risankizumab
Description: Placebo for risankizumab is administered as a SC injection in PFS
Study NCT02251652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ingenol Mebutate
Description: Ingenol mebutate 0.05% gel
Study NCT02251652 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: 1-2 sprays, 5 seconds each, with a 5 second interval
Study NCT03253497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorobenzene Liquid
Description: before induction will be used for oropharynx
Study NCT03328312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Time period from administration of the reversal agent to recovery of TOFR >0.9
Study NCT03328312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: neostigmine+atropine
Description: Number and time of bradycardic episodes (HR\<60 bpm) as well as that of tachycardic episodes (HR>100 bpm) before tracheal extubation
Study NCT03328312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neostigmine+atropine+sugammadex
Description: 4. Time of extubation
Study NCT00828347 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 1.0 μg/day Alfacalcidol
Description: We compared the efficacy of two protocols for maintenance therapy, which were oral administration of alfacalcidol at a dose of 1.0 μg/day in patients whose iPTH level was controlled to \< 150 pg/mL by initial maxacalcitol therapy.
Study NCT00828347 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 0.25 μg/day Alfacalcidol
Description: We compared the efficacy of two protocols for maintenance therapy, which were oral administration of alfacalcidol at a dose of 0.25 μg/day in patients whose iPTH level was controlled to \< 150 pg/mL by initial maxacalcitol therapy.
Study NCT02490228 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: TAURFUC
Description: female patients with urethral caruncle will receive transurethral resection combine with extension tube.
Study NCT02959931 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Potassium Meal
Description: Breakfast meal that provides \~2400 mg of dietary potassium. Meals are isocaloric.
Study NCT02959931 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Potassium Meal
Description: Breakfast meal that provides \~540 mg of potassium. Meals are isocaloric.
Study NCT03918083 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wellness
Description: Assess the feasibility of an integrated, prescriptive, and trackable wellness intervention amongst residents at Orange Park Medical Center (OPMC) by combining five wellness elements including: exercise, mindfulness, sleep, social connectedness, and nutrition.
Study NCT02853110 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypo-FLAME study
Description: SBRT technique with 35 Gy in 5 weekly fractions and an additional simultaneously integrated focal boost to the tumor nodule(s) visible on MRI up to 50 Gy. In addition, patients will be asked to undergo 5 additional MRI scans (\~15 min/scan) without contrast enhancement prior to each radiation session as well as blood sampling for translational research (radiogenomics) and Biobank purposes.
Study NCT05373368 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multi purpose activities
Study NCT02420431 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive Therapy
Description: Metacognitive therapy (MCT) helps clients to identify episodes of worry and rumination in response to negative thoughts and bring these responses under control. This process is facilitated by exercises that enhance the flexibility of attention control, challenge unhelpful beliefs about thinking and enable new relationships with thoughts
Study NCT02420431 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Rehabilitation (treatment as usual)
Description: Stress management, relaxation training, exercise and dietary advice.
Study NCT05055011 — intervention group
Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Review of medical records
Study NCT05055011 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study NCT04299503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crisaborole Topical Ointment
Description: For every 10% of scalp affected, approximately ½ finger tip of study drug will be needed to cover the area with a thin layer. After the first application at baseline, the tubes will be weighed to determine the dose needed to cover the affected area. This will be the subject's target dose throughout the study
Study NCT04299503 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Topical Ointment
Description: For every 10% of scalp affected, approximately ½ finger tip of study drug will be needed to cover the area with a thin layer. After the first application at baseline, the tubes will be weighed to determine the dose needed to cover the affected area. This will be the subject's target dose throughout the study
Study NCT01257997 — intervention group
Intervention type: BIOLOGICAL
Intervention: 15N-Thymidine, 2H-Water
Description: Stable isotope 15N-thymidine, infused IV (15mg/hour) for 72 hours (phase 1 pilot).~Stable isotope 2H-water, ingested by mouth once per day for 3 days (phase 1 pilot) or 28 days (phase 2 pilot).
Study NCT02387060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H-Bupivacaine
Description: Intrathecal administration of hyperbaric bupivacaine 1.5 ml 0.75%
Study NCT02387060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: H-Bupivacaine
Description: Intrathecal administration of hyperbaric bupivacaine 1.5 ml 0.75%
Study NCT02387060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Intrathecal administration of fentanyl 25 mcg
Study NCT01716767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menthol
Description: The gel will be applied at 2.5 ml per 500 cm2 to the hand, wrist and forearm
Study NCT00748618 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Standard vitamin D3 treatment
Description: 10,000 I.U./wk of vitamin D3 orally for 6 months
Study NCT00748618 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High dose vitamin D3 treatment
Description: 50,000 I.U./wk of vitamin D3 orally for 6 months
Study NCT01826539 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: flap includes a donor nerve
Description: the donor nerve is attached with the flap for sensory reconstruction of the finger
Study NCT03946774 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary protein shake
Description: It is a milk based protein shake. Ingredients include a combination of the following depending on protein content: Boost Plus (a commercial supplement), Unjury (a commercial whey protein isolate), nonfat dry milk powder, Sol Carb (commercial supplement composed of a carbohydrate polymer), canola oil, and water.~In order to ensure consistency across all participants each beverage will be prepared in the Clinical Translational Research Unit Metabolic Kitchen under the supervision of a registered dietitian prior to the study participant's visit. Ingredients are individually weighed on a food scale by metabolic kitchen staff to the nearest 0.1 g and then mixed using a magnetic stir plate.~Nutritional breakdown of the smoothies (high versus low protein):~High protein drink nutrition: 500 kcal per serving, 50% protein, 17% fat, and 36% carbohydrate.~Low (standard) protein drink nutrition: 500 kcal per serving, 10% protein, 17% fat, and 73% carbohydrate.
Study NCT04042909 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counter Attitudinal Advocacy
Description: same as Counter Attitudinal Advocacy arm
Study NCT04042909 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personalized Normative Feedback
Description: same as Personalized Normative Feedback arm
Study NCT03066323 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rice with tea extract
Description: Rice with tea extract
Study NCT03066323 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rice without tea extract
Description: Rice without tea extract
Study NCT01780246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nusinersen
Description: Administered by intrathecal (IT) injection
Study NCT03850093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin1200 mg
Description: patients received 1200mg gabapentin 2 hrs preoperative
Study NCT03850093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bisoprolol 2.5mg
Description: patients received 2.5mg bisoprolol 2 hrs preoperative
Study NCT03850093 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: patients received oral placebo 2 hrs preoperative
Study NCT02594930 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: synovial biopsy of total knee arthroplasty
Description: synovial biopsies are taken via two different techniques in the same patient to allow direct comparison of results
Study NCT02697240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous citrulline
Description: Intravenous citrulline at a bolus dose of 20 mg/kg over 5 minutes and then continuous at a rate of 7 mg/kg/hour for the next 23 hours for the first 7 participants, and depending on safety and pharmacokinetic profile, increase or decrease the continuous rate to 9 or 5 mg/kg/hour for the next 7 participants.
Study NCT03766412 — intervention group
Intervention type: OTHER
Intervention: High School start time
Description: The time that the school starts
Study NCT01210612 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unilateral CAI
Description: five-toed socks usage
Study NCT01210612 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Unilateral CAI
Description: five-toed socks usage
Study NCT00405808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimonabant
Description: Once daily in the morning
Study NCT01716767 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The gel will be applied at 2.5 ml per 500 cm2 to the hand, wrist and forearm
Study NCT00405808 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily in the morning
Study NCT01956305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-7309
Description: DS-7309 powder in bottle
Study NCT00560859 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adenotonsillectomy (AT) - removal of adenoids and tonsils
Description: Standard surgical intervention for treatment of Obstructive Sleep Apnea Syndrome which includes removal of adenoids and tonsils
Study NCT00560859 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Watchful Waiting
Description: Children will reevaluated for adenotonsillectomy (AT) after a 7 month primary monitoring period.
Study NCT01956305 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo to match DS-7309 powder in bottle
Study NCT01956305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 500mg tablet for Cohort F
Study NCT00753857 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug Facts Box
Description: Educational intervention of 1 page summary of drug efficacy and side effects
Study NCT00753857 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Brief Summary
Description: Ads consisted of the standard second page called the brief summary
Study NCT00080873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traumeel S
Study NCT00080873 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02304133 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Education
Study NCT01691781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Description: Each subject will receive one week of lisinopril and return for repeat for blood measurements.
Study NCT00996645 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Worksheet to facilitate goal-setting and action plans
Description: Developed based on goal-setting theory and implementation intentions, the worksheet will be mailed out with the feedback reports and is expected to facilitate improved quality of care in response to feedback reports.
Study NCT01082991 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Preemptive Rapid Response Team intervention
Description: Non-ICU inpatients will be randomized on admission to an RRT surveillance group or standard of care. Daily risk prediction scores will be collected for all non-ICU inpatients. Those with high scores, who have been randomized to the surveillance arm, will be included on a list of patients, updated daily, that the Rapid Response Team will receive, with instructions to evaluate and intervene, if required, without waiting for formal activation by the usual channels.
Study NCT04110301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Humanized Monoclonal Antibody MIL62 Injection
Description: 1000mg /dose for 12 cycles(28 days) and a total of 11 doses :the first Cycle(Day1,Day15), the 2nd-8th Cycles(Day 1 every cycle);the 9th-12nd Cycles (One dose every two cycles).
Study NCT04110301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Dose on days 2-22 every 28 days x 12 cycles: the starting dose is 10-mg ; Adjusted dose according to the tumor response or toxicity reaction
Study NCT02689141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Induction: Cycle 2-6: d1-28: 420 mg p.o. Maintenance: After the induction ibrutinib p.o. 420 mg daily will be continued. Cycle 1-8: d1-84: 420 mg p.o.
Study NCT02738294 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ME-NBI observation and ME-NBI targeted biopsy
Description: The endoscopist assessed lesions which were suspected EGC carefully with ME-NBI. After assessing suspected EGC in ME-NBI view, ME-NBI targeted biopsy was performed where abnormal phenomenon was identified in ME-NBI view.
Study NCT02304133 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Study NCT03063918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive a workbook
Study NCT03063918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03063918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03063918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT03063918 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive personalized dietary intervention
Study NCT02204306 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: TSER
Description: TS gene will be genotyped for each patients prior to chemotherapy. Patients will be assigned to different arms according to specific TSER genotype.
Study NCT04326621 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pressure Release Technique (PRT)
Description: A pressure applied on muscles trigger points with the finger of a physiotherapist and exercises
Study NCT04326621 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pressure Release Technique (PRT)
Description: A pressure applied on muscles trigger points with the finger of a physiotherapist and exercises
Study NCT00656994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 16 mg, tablets, orally, once nightly for up to 6 months.
Study NCT00656994 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ramelteon placebo-matching tablets, orally, once nightly for up to 6 months
Study NCT04326621 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: exercises
Study NCT02783651 — intervention group
Intervention type: OTHER
Intervention: Other
Description: No intervention other than routine medical care
Study NCT02052154 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prime-boost pneumococcal immunization
Description: 2 months between the 2 vaccines
Study NCT01293214 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Limb transplantation
Study NCT04326621 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: exercises
Study NCT02771535 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: D-MCT
Description: Metacognitive Training for Depression (D-MCT), 8 sessions (60min); twice a week over a period of 4 weeks. Metacognitive Training for depression (D-MCT) is a low-threshold, easy to administer group intervention. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research.
Study NCT02771535 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Training
Description: Health Training Group (Walking/ Psychoeducation on health); 8 sessions (60min), twice a week over a period of 4 weeks
Study NCT04676659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNK-tPA
Description: Experimental arms for low, middle, and high dosing; and active control arm for the standard protocol
Study NCT04676659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TNK-tPA
Description: Experimental arms for low, middle, and high dosing; and active control arm for the standard protocol
Study NCT03630107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WO 5101 Shampoo for Scalp and Hair
Description: Wash the hair at least three times a week for a period of four weeks
Study NCT03851224 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: immediate implant with immediate loading using no graft
Study NCT03851224 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: study group
Description: immediate implant with immediate loading using autogenous bone graft
Study NCT03851224 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: study group 2
Description: immediate implant with immediate loading using (Geistlich Bio-Oss®) xenograft
Study NCT01998906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8mg/kg IV on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of Cycle 2 up a maximum of Cycle 17
Study NCT01039324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reports
Description: Primary care event reports and patient letters
Study NCT01039324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reports and Notices
Description: Primary care event reports, patient letters and care manager notices
Study NCT01998906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 60 mg/m2 IV on Day 1 of Cycles 1 through 3
Study NCT01998906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60 mg/m2 IV on Day 1 of Cycles 1 through 3
Study NCT01998906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 150 mg/m2 IV on Day 1 of Cycles 1 through 3, followed by 175 mg/m2 IV on Day 1 of Cycles 4 through 7
Study NCT01998906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 150 mg/m2 IV on Day 1 of Cycles 1 through 3, followed by 175 mg/m2 IV on Day 1 of Cycles 4 through 7
Study NCT01998906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CMF
Description: CMF: Cyclophosphamide (600 mg/m2 IV bolus), methotrexate (40 mg/m2 IV bolus), 5-fluorouracil (600 mg/m2 IV bolus) on Day 1 of Cycles 8 through 10
Study NCT01998906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMF
Description: CMF: Cyclophosphamide (600 mg/m2 IV bolus), methotrexate (40 mg/m2 IV bolus), 5-fluorouracil (600 mg/m2 IV bolus) on Day 1 of Cycles 8 through 10
Study NCT01039324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: This is the study's control group
Study NCT01463696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8242
Description: 10 mg, 100 mg and 150 mg capsules
Study NCT04597645 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic elastic band resistance training
Description: A16-week therapeutic program using Elastic Thera Band will be taught. The exercises are designed to train specific major muscle groups, strengthen the motivation of participants, and facilitate home-based compliance. The program will be performed two times per week (once supervised and guided by a trained physical therapist and the other supervised by educational trainers) over 16 weeks for a total of 32 sessions. Each session supervised by a physical therapist last for 60 minutes, including a 5-minute warm-up consisting of light-intensity aerobic and dynamic stretching exercises, followed by 50 minutes of EB exercise and a 5-minute period of cool-down and static stretching exercises.
Study NCT00971581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC KETOPROFEN+OMEPRAZOLE
Description: Ketoprofen + Omeprazole FDC once daily for 4 weeks